GlassScriptPhysician profile
Glenn Howard Englander
NPI 1932166543
$9,525.19
in general payments reported to CMS, 2019-2025
27 companies · $1,826 in 2025
The $1,826 reported for 2025 was more than what 77% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,463 · 2020: $925 · 2021: $1,135 · 2022: $1,666 · 2023: $1,718 · 2024: $793 · 2025: $1,826.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,238 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,237.72 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,899.43 | 2019-2025 | |
| Janssen Biotech, INC. | $1,257.90 | 2019-2025 | Stelara, Tremfya, Remicade |
| Gilead Sciences, INC. | $1,203.51 | 2019-2025 | Livdelzi |
| Pfizer INC. | $918.68 | 2019-2025 | |
| Celgene Corporation | $680.27 | 2021-2024 | Zeposia |
| Boston Scientific Corporation | $477.68 | 2019-2025 | Axios, Exalt Model D, Acquire |
| Takeda Pharmaceuticals U.S.A., INC. | $466.19 | 2019-2024 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $461.56 | 2019-2025 | Xifaxan, Trulance |
| Intercept Pharmaceuticals, INC. | $283.33 | 2019-2025 | Ocaliva |
| Phathom Pharmaceuticals, INC. | $278.84 | 2024 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $225.14 | 2021-2023 | Zeposia |
| Medtronic, INC. | $221.95 | 2023 | Interstim |
| Ironwood Pharmaceuticals, INC | $212.41 | 2019-2023 | Linzess |
| Janssen Scientific Affairs, LLC | $166.25 | 2019-2025 | Tremfya |
| Madrigal Pharmaceuticals | $158.49 | 2025 | Rezdiffra |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $117.64 | 2025 | Wegovy |
| Regeneron Healthcare Solutions, INC. | $109.43 | 2023-2024 | Dupixent |
| Redhill Biopharma INC. | $99.52 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $90.68 | 2021-2024 | Dificid |
| Allergan, INC. | $49.81 | 2019-2020 | |
| Shire North American Group INC | $44.45 | 2019 | |
| Ardelyx, INC. | $24.00 | 2025 | Ibsrela |
| Ferring Pharmaceuticals INC. | $22.69 | 2023 | Rebyota |
| Vivus LLC | $16.90 | 2022 | |
| Micro-Tech Endoscopy USA, INC. | $14.33 | 2023 | Valve Kits |
| Braintree Laboratories, INC. | $12.39 | 2022 | |
| Ambu INC. | $11.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glenn Englander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.